false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Critica ...
Preventing AKI in Cardiac Surgery: What Can We Act ...
Preventing AKI in Cardiac Surgery: What Can We Actually Implement Tomorrow?
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Alex Zarbock discussed preventing acute kidney injury (AKI) after cardiac surgery. AKI affects up to 40% of patients and is associated with higher mortality, healthcare use, and long-term risks of chronic kidney disease—even when kidney function appears to recover. Its causes include cardiopulmonary-bypass-related ischemia and inflammation, hemodynamic disturbances, nephrotoxic drugs, and patient comorbidities.<br /><br />Traditional risk scores have limitations, while biomarkers—particularly TIM-2·IGF-BP7—can help identify high-risk patients early. Zarbock highlighted trials showing that a multimodal, KDIGO-based kidney-protection strategy can reduce moderate-to-severe AKI. Measures include optimizing hemodynamics, stopping nephrotoxic medications when possible, monitoring creatinine and urine output, and avoiding hyperglycemia. In the BigpAK-2 trial, the strategy reduced moderate-to-severe AKI from 22% to 15%.<br /><br />He also reviewed remote ischemic preconditioning, which his team uses in selected high-risk patients. Evidence for perioperative amino acids and SGLT2 inhibitors remains uncertain, and he cautioned that observed reductions in AKI may not demonstrate true kidney protection. In discussion, he emphasized assessing volume status and cardiac output—not just maintaining mean arterial pressure above 65 mmHg—and said further trials are needed to establish which strategies improve outcomes in routine practice.
Asset Caption
Alexander Zarbock, MD
Meta Tag
Speaker
Alexander Zarbock
Keywords
acute kidney injury
cardiac surgery
KDIGO
biomarkers
TIM-2·IGF-BP7
BigpAK-2 trial
remote ischemic preconditioning
×
Please select your language
1
English